SA
Log In
NTRA
OverviewIntelligenceChart
Earnings in 1 day · May 7, 2026 · After close
Signal
Mixed1↑1↓
Price
1↓
Move↓-2.26%Negative session
Volume
1→
Volume→0.9× avgNormal activity
Technical
1↑
RSI↑RSI 58Momentum positive
PRICE
Prev Close
211.56
Open
211.36
Day Range205.01 – 213.84
205.01
213.84
52W Range131.81 – 256.36
131.81
256.36
60% of range
VOLUME & SIZE
Avg Volume
1.2M
FUNDAMENTALS
P/E Ratio
-136.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.68
High vol
Quick Read
Trend—Insufficient MA data
Momentum
BULLISH
revenue +36% YoY · 65% gross margin
Valuation
FAIR
P/E not available
Health
STRONG
CR 3.4 · FCF $0.71/sh
Strong Buy
Key MetricsTTM
Market Cap$29.31B
Revenue TTM$2.31B
Net Income TTM-$208.16M
Free Cash Flow$96.61M
Gross Margin64.8%
Net Margin-9.0%
Operating Margin-13.4%
Return on Equity-15.3%
Return on Assets-8.3%
Debt / Equity0.13
Current Ratio3.39
EPS TTM$-1.52
Alpha SignalsView Intelligence →

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
49/100
Liquidity
3.39Strong
Leverage
0.13Strong
Coverage
-30.3xConcern
ROE
-15.3%Concern
ROIC
-11.1%Concern
Cash
$1.1BStrong
ANALYST COVERAGE27 analysts
BUY
▲ +30.6%upside to target
L $205.00
Med $270.00consensus
H $285.00
Buy
2593%
Hold
27%
25 Buy (93%)2 Hold (7%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
●
RSI RangeRSI 58 — Bullish momentum
✓
Fundamentals
●
Last EarningsBeat estimates
✓
●
Analyst ConsensusBuy
✓
●
LiquidityCurrent Ratio 3.39 — healthy liquidity
✓

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings Report · Before OpenMay 7, 2026
Tomorrow
DEx-Dividend DateAug 4, 2026
In 90 days
PDividend PaymentSep 1, 2026
In 118 days
Research
Fundamentals→Financials→Analysts→Earnings→Growth→Key Metrics→Technical Analysis→Intelligence→
Technicals
Technical SetupBULLISH
Technicals →

Trend

▲ UptrendGolden Cross · 50D leads 200D by 5.4%

+1.3% vs SMA 50 · +6.8% vs SMA 200

Momentum

RSI57.5
Positive momentum, not extended
MACD+0.88
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$256.4+24.0%
Current
$206.8
EMA 50
$205.9-0.4%
EMA 200
$190.9-7.7%
52W Low
$131.8-36.3%
52-Week RangeMid-range
$131.860th %ile$256.4
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 14 analysts
Full estimates →
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$2.2B
$2.2B–$2.3B
—-$2.40—
±9%
High12
FY2026(current)
$2.7B
$2.6B–$2.7B
▲ +19.0%-$1.78—
±26%
High14
FY2027
$3.2B
$3.1B–$3.3B
▲ +19.6%-$0.61—
±50%
High14
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryNTRA
Last 8Q
+28.6%avg beat
Beat 5 of 8 quartersMissed 3↑ Estimates rising
+21%
Q2'24
+57%
Q3'24
+54%
Q4'24
-8%
Q1'25
+22%
Q2'25
-20%
Q3'25
-66%
Q4'25
+168%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Cowen & Co.Buy
Dec 11
UPGRADE
Exane BNP ParibasNeutral
Oct 27
UPGRADE
BernsteinOutperform
Apr 5
UPGRADE
Raymond JamesStrong Buy
Nov 13
UPGRADE
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $5.6M sold · 30d window
Brophy Michael Burk…CFO
$65K
May 1
SELL
Brophy Michael Burk…CFO
$101K
May 4
SELL
Sheena JonathanDir
$22K
May 1
SELL
Moshkevich SolomonPRESIDENT, CLI…
$83K
May 1
SELL
Moshkevich SolomonPRESIDENT, CLI…
$113K
May 1
SELL
Moshkevich SolomonPRESIDENT, CLI…
$105K
May 1
SELL
Financials

INSTITUTIONAL OWNERSHIP

13-F Filings →
1
Sumitomo Mitsui Trust Holdings, Inc.
692K▼
2
Bank of New York Mellon Corp
670K▲
3
Nuveen, LLC
475K▼
4
Allspring Global Investments Holdings, LLC
463K▲
5
UBS Group AG
423K▼
6
Robeco Institutional Asset Management B.V.
406K▲
7
PRINCIPAL FINANCIAL GROUP INC
311K▼
8
ENVESTNET ASSET MANAGEMENT INC
267K▲
News & Activity

NTRA News

20 articles · 4h ago

About

Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform.

Sector
Health Care and Social Assistance
Industry
Medical Laboratories
Website
www.natera.com ↗
John FeskoPresident & Chief Business Officer
Solomon MoshkevichPresident of Clinical Diagnostics

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance